Royalty Pharma (RPRX) Expected to Announce Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) will likely be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Royalty Pharma to announce earnings of $1.18 per share and revenue of $884.84 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The business had revenue of $674.14 million for the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. On average, analysts expect Royalty Pharma to post $5.29 EPS for the current fiscal year and $5.64 EPS for the next fiscal year.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $67.18 on Monday. The stock has a market capitalization of $38.63 billion, a PE ratio of 46.33, a P/E/G ratio of 1.84 and a beta of 0.36. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. The business has a fifty day moving average price of $60.28 and a two-hundred day moving average price of $53.13. Royalty Pharma has a fifty-two week low of $36.03 and a fifty-two week high of $67.71.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $0.2350 per share. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, November 13th. Royalty Pharma’s dividend payout ratio is 64.83%.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of recent analyst reports. Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, September 14th. Morgan Stanley upped their price objective on shares of Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. TD Cowen increased their price objective on shares of Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Finally, JPMorgan Chase & Co. raised their target price on shares of Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating. According to MarketBeat, Royalty Pharma currently has an average rating of “Buy” and a consensus price target of $61.57.

Insider Buying and Selling at Royalty Pharma

In related news, EVP Marshall Urist sold 4,126 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the company’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the sale, the executive vice president owned 270,401 shares of the company’s stock, valued at approximately $15,826,570.53. This represents a 27.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 208,252 shares of company stock worth $12,324,407. Corporate insiders own 18.84% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.